Men with PIRADS Score ≤ 3 and SelectMDx Score $\leq 30\%$ can be Spared from Prostate Biopsy

University of Colorado Anschutz Medical Campus, Aurora, CO, *Prostate Condition Education Council, Aurora, CO,

Whitney N. Stanton, Priva N. Werahera, PhD, Paul B. Arangua, Francisco G. La Rosa, MD, Gretchen P. Hoyer, Adrie van Bokhoven, PhD, M. Scott Lucia, MD, Wendy L. Poage*, Samuel Chang, MD, Nelson N. Stone**, and E. David Crawford, MD

**Mount Sinai School of Medicine, Suffern, NY

- significant (CS) prostate PCa
- 18/34 (53%) had CS PCa. (Fig B)




Fig A: TMB

- mpMRI classified using PIRADS scores (Fig C)
- curves.

• Evaluated combined utility of PIRADS score and biomarkers to identify high grade (HG) and clinically


• Used histopathology of 5 mm grid interval transperineal mapping biopsy (TMB) as reference (Fig. A) • TMB identified 34/39 (87%) patients with prostate cancer, 15/34 (44%) had high grade prostate cancer, and


• Serum and post-DRE urine used for phi and Select MDx tests

Fig B: Histopathology

• Multivariate logistic regression analyses (MLRA) and receiver operating characteristic (ROC) curves were used to determine diagnostic accuracy. DeLong test was used to determine statistical significance of ROC

Fig C: PIRADS






Source of Funding: The study was supported in parts by the Bingham Research Fund and Schramm Foundation

x > 0%	phi ≥ 27		$PIRADS \ge 3$		
CS PCa	HG PCa	CS PCa	HG PCa	CS PCa	
67%	93%	94%	93%	94%	
81%	29%	33%	21%	24%	
28%	10%	14%	9%	12%	
96%	98%	98%	97%	97%	
74%	54%	62%	49%	56%	
0.75	0.81	0.75	0.72	0.66	
0.8	0.84	0.8	-	-	

Variable	AUC	SE ^a	95% C	i p	
SelectMDx	0.832	0.0675	0.678 to 0.9	32	
PHI	0.808	0.0774	0.651 to 0.9	16	
PIRADS	0.718	0.0799	0.551 to 0.8	50	
PSA	0.742	0.0834	0.577 to 0.8	68	
PSAD	0.722	0.0859	0.556 to 0.8	53	
P2PSA DeLong et al., 198 Binomial exact		0.0870 iable	0.532 to 0.8		95% CI
DeLong et al., 198	88 Var	iable	AUC	36 SE ^a	PERSONAL PROPERTY AND ADDRESS OF ADDRES ADDRESS OF ADDRESS OF ADDR
DeLong et al., 198	88 Var PIR	iable	AUC 0.718	36 SE ^a 0.0799	0.551 to 0.850
DeLong et al., 198	88 Var PIR PIR	iable	AUC 0.718 0.792	36 SE ^a	0.551 to 0.850 0.632 to 0.905
DeLong et al., 198	88 Var PIR PIR	iable ADS ADS_PSAD	AUC 0.718 0.792	36 SE ^a 0.0799 0.0767	0.551 to 0.850 0.632 to 0.905 0.742 to 0.964
DeLong et al., 198	88 Var PIR PIR PIR	iable ADS ADS_PSAD ADS_SELMDX	AUC 0.718 0.792 0.885	36 SE ^a 0.0799 0.0767 0.0658	95% CI 0.551 to 0.850 0.632 to 0.905 0.742 to 0.964 0.693 to 0.940 0.619 to 0.897

- the respective diseases.





• Both phi \ge 27 and PIRADS score \ge 3 show very high sensitivity for HG and CS cancer (shown in red), but very low specificity SelectMDx shows high sensitivity and NPV for HG and CS cancer (shown in green) mpMRI has very high sensitivity, but low specificity for HG and CS PCa. SelectMDx test has high specificity to identify men without

• Thus, men with PIRADS \leq 3 and **SelectMDx ≤ 30% can be spared from** unnecessary prostate biopsy.